- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00502853
A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
7 juillet 2017 mis à jour par: Hoffmann-La Roche
Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.
This single arm study will measure the effect of MabThera in combination with methotrexate on the progression of synovitis, the extent of bone marrow edema, and the number of erosions in the wrist and hand of patients with rheumatoid arthritis, using a new MRI technique.
Patients will receive MabThera 1000mg i.v. on days 1 and 15, in combination with a stable dosage of 10-25mg/week methotrexate throughout the duration of the study.
Further courses of MabThera will be provided to eligible patients.
MRI will be performed 1-2 weeks before treatment initiation, and repeated 1 and 6 months after the first MabThera infusion.
The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
10
Phase
- Phase 4
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Liguria
-
Genova, Liguria, Italie, 16132
- Università Degli Studi Di Genova - Dimi; Reumatologia
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 75 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- adult patients, 18-75 years of age;
- rheumatoid arthritis for >=3 months and <=10 years;
- inadequate response to methotrexate (12.5-25mg/week) for >=3 months;
- evidence of erosive disease and/or clinical synovitis in a signal joint.
Exclusion Criteria:
- autoimmune rheumatic diseases other than RA;
- surgical operations on bones/joints in 12 weeks prior to baseline visit;
- concomitant treatment with biologic agents;
- previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: 1
|
1000mg iv les jours 1 et 15
10-25mg/semaine
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score
Délai: Baseline, Week 4, and Week 24
|
Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT.
Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium.
Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint.
1st carpometacarpal joint and 1st MCP joint are not scored.
Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.
Total synovitis score=the sum of the individual scores (3 wrist regions [range 0-9] or 4 MCP joints [range 0-12]) for an overall range of 0-21, where 0=no damage and maximum score [9, 12, or 21]=most severe damage.
Change in synovitis = Follow-up synovitis score - baseline score.
|
Baseline, Week 4, and Week 24
|
OMERACT RAMRIS Bone Edema Score
Délai: Baseline, Weeks 4 and 24
|
Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT.
Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content.
Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately.
The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous.
Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema.
Change in bone edema = follow-up bone edema score - baseline score.
|
Baseline, Weeks 4 and 24
|
OMERACT RAMRIS Erosion Score
Délai: Baseline, Week 4, and Week 24
|
MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane.
Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately.
Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc).
For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone.
Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion.
Change in erosion=Follow-up erosion score - baseline score.
|
Baseline, Week 4, and Week 24
|
Early Enhancement Rate (REE)
Délai: Baseline, Weeks 4 and 24
|
A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints.
In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI, i.e.
Contrast-Enhanced Dynamic MRI (DCE-MRI).
This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane.
Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its "steady state" condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%.
The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher.
|
Baseline, Weeks 4 and 24
|
Relative Enhancement (RE) Score
Délai: Baseline, Weeks 4 and 24
|
A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints.
In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI (DCE-MRI).
This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane.
Numerical parameters used with this method are the slope in the initial phase (REE) and its "steady state" condition (RE).
|
Baseline, Weeks 4 and 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Ritchie Articular Index Scores
Délai: Baseline and Weeks 4, 12, and 24
|
The Ritchie Articular Index is a graded assessment of tenderness in 26 joint regions.
The sum of the grades of tenderness (0=not tender, 1=tender, 2=tender and causes wince, and 3 tender, causes wince and effort to withdraw) elicited by applying firm pressure over the joint margin of articular joints (such as shoulders, elbow, wrists, hips).
The scores ranged from 0 (no tenderness) to 78 (most severe tenderness).
|
Baseline and Weeks 4, 12, and 24
|
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
Délai: Baseline and Weeks 4, 12, and 24
|
The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis (RA).
It consist of 20 items referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Each item within a domain was scored on a 4-point Likert scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do.
The highest score reported by the participant for a domain determined the score for that domain.
The overall disability index is computed as the sum of domain scores and divided by the number of domains answered.
Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
|
Baseline and Weeks 4, 12, and 24
|
Patient's Global Assessment of Pain
Délai: Baseline and Weeks 4, 12, and 24
|
The participant's assessment of their current level of pain on a 0 to 100 millimeter (mm) horizontal VAS.
The left-hand extreme of the line was described as "no pain" and the right-hand as "unbearable pain".
The participant was asked to mark the line corresponding to their current level of pain and the distance from the left edge was recorded.
|
Baseline and Weeks 4, 12, and 24
|
DAS28 Score
Délai: Baseline and Weeks 4, 12, and 24
|
DAS28 calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity.
A DAS28 score of less than or equal to (≤) 3.2 = low disease activity, a DAS28 score of >3.2 to 5.1 = moderate to high disease activity.
|
Baseline and Weeks 4, 12, and 24
|
Erythrocyte Sedimentation Rate (ESR)
Délai: Baseline and Weeks 4, 12, and 24
|
ESR was determined using the Westergren method.
ESR measures how fast red blood cells (erythrocytes) fall to the bottom of a fine glass tube that is filled with the participant's blood.
The higher the sedimentation rate the greater the inflammation.
|
Baseline and Weeks 4, 12, and 24
|
C-Reactive Protein (CRP)
Délai: Baseline and Weeks 4, 12, and 24
|
CRP measured by milligrams per deciliter (mg/dL).
High levels of CRP are indicators of active inflammation.
|
Baseline and Weeks 4, 12, and 24
|
Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count
Délai: Baseline and Weeks 4, 12, and 24
|
Anti-CCP autoantibodies count measured by units per milliliter (U/mL).
The anti-CCP autoantibodies bind antigenic determinants that contain the unusual amino acid citrulline.
The anti-CCP antibody is a highly specific diagnostic test of RA (though with variable sensitivity) and a marker of joint damage with high prognostic significance.
|
Baseline and Weeks 4, 12, and 24
|
Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations
Délai: Baseline and Weeks 4, 12, and 24
|
RF IgM concentrations measured by international units per milliliter (IU/mL).
RF is an antibody reacting against the fragment, crystallizable (Fc) region of IgG.
Quantitative measurements have shown a prognostic value in distinguishing between progressive and non-progressive disease in early RA, a correlation with radiologically determined joint damage, and relation with clinical improvement after disease-modifying anti-rheumatic treatment.
|
Baseline and Weeks 4, 12, and 24
|
Total Immunoglobulin (Ig) Concentrations
Délai: Baseline and Weeks 4, 12, and 24
|
Total Ig concentrations as measured by milligrams per milliliter (mg/mL).
|
Baseline and Weeks 4, 12, and 24
|
Hematocrit Concentration (%)
Délai: Baseline and Weeks 4, 12, and 24
|
Baseline and Weeks 4, 12, and 24
|
|
Percentage of Total B-lymphocytes
Délai: Baseline and Weeks 4, 12, and 24
|
Concentration of all B-lymphocytes subtypes was assessed.
|
Baseline and Weeks 4, 12, and 24
|
Erosion Score - Right Hand
Délai: Baseline and Week 24
|
The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved.
A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone.
A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected.
In each joint, individual erosions were summed up to a maximum of 5.
The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.
|
Baseline and Week 24
|
Erosion Score - Left Hand
Délai: Baseline and Week 24
|
The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved.
A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone.
A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected.
In each joint, individual erosions were summed up to a maximum of 5.
The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.
|
Baseline and Week 24
|
Joint Space Narrowing - Right Hand
Délai: Baseline and Week 24
|
Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing.
A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 times [x] 4 [maximum per joint]).
Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).
|
Baseline and Week 24
|
Joint Space Narrowing - Left Hand
Délai: Baseline and Week 24
|
Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing.
A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 x 4 [maximum per joint]).
Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).
|
Baseline and Week 24
|
X-Rays: Right Hand Total Score
Délai: Baseline and Week 24
|
Right hand total scores as measured by X-rays examining erosion and joint space narrowing.
Total score was calculated as the sum of the erosion score and the joint space narrowing score and scores ranged from 0 (best possible outcome) to 180 (worst possible outcome).
|
Baseline and Week 24
|
X-Rays: Left Hand Total Score
Délai: Baseline and Week 24
|
Left hand total scores as measured by X-rays examining erosion and joint space narrowing.
Total score was calculated as the sum of the erosion score and the joint space narrowing score and ranged from 0 (best possible outcome) to 180 (worst possible outcome).
|
Baseline and Week 24
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
25 octobre 2007
Achèvement primaire (Réel)
23 juillet 2010
Achèvement de l'étude (Réel)
23 juillet 2010
Dates d'inscription aux études
Première soumission
17 juillet 2007
Première soumission répondant aux critères de contrôle qualité
17 juillet 2007
Première publication (Estimation)
18 juillet 2007
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
16 août 2017
Dernière mise à jour soumise répondant aux critères de contrôle qualité
7 juillet 2017
Dernière vérification
1 juin 2017
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Maladies auto-immunes
- Maladies articulaires
- Maladies musculo-squelettiques
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Arthrite
- Arthrite, rhumatoïde
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs de la synthèse des acides nucléiques
- Inhibiteurs d'enzymes
- Agents antirhumatismaux
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents antinéoplasiques immunologiques
- Agents dermatologiques
- Agents de contrôle de la reproduction
- Agents abortifs, non stéroïdiens
- Agents abortifs
- Antagonistes de l'acide folique
- Rituximab
- Méthotrexate
Autres numéros d'identification d'étude
- ML21081
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur rituximab [MabThera/Rituxan]
-
University of VermontGenentech, Inc.ComplétéMyasthénie grave réfractaireÉtats-Unis
-
Hoffmann-La RocheComplétéLymphome non hodgkinienItalie, Brésil, Slovénie, Espagne, Allemagne, Suisse, Fédération Russe, Israël, Suède, Albanie, Argentine, Australie, Bosnie Herzégovine, Bulgarie, Colombie, Croatie, Equateur, Egypte, Finlande, Grèce, Mexique, Roumanie, Slovaquie, Tur...
-
Hoffmann-La RocheComplétéPurpura thrombocytopénique idiopathiqueAustralie
-
Hoffmann-La RocheComplété
-
Hoffmann-La RocheComplétéLa polyarthrite rhumatoïdeFinlande
-
East Carolina UniversityGenentech, Inc.ComplétéProtéinose alvéolaire pulmonaire | Maladie primaireÉtats-Unis
-
Hoffmann-La RocheComplété
-
Hoffmann-La RocheComplétéLymphome non hodgkinienFrance
-
Hoffmann-La RocheComplété
-
Medical University of ViennaRésilié